Efficacy and safety of interferon and ribavirin therapy in HIV-HCV coinfected patients

被引：2
|
作者：
Zylberberg, H
Benhamou, Y
Chaix, ML
Fontaine, H
Rouzioux, C
Katlama, C
Poynard, T
Bréchot, C
Pol, S
机构：
[1] CHU Necker, INSERM, U370, Liver Unit,CHU Pitie Salpetriere, F-75015 Paris, France
[2] CHU Necker, INSERM, U370, Virol Lab,CHU Pitie Salpetriere, F-75015 Paris, France
来源：
JOURNAL OF HEPATOLOGY | 2000年 / 32卷
关键词：
D O I：
10.1016/S0168-8278(00)81007-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：178 / 178
页数：1
相关论文
共 50 条
  • [41] Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients
    Hatu, Giorgiana
    Bailly, Francois
    Pourcelot, Emmanuel
    Pradat, Pierre
    Miailhes, Patrick
    Maynard, Marianne
    Parant, Francois
    Chiarello, Pierre
    Livrozet, Jean-Michel
    Zoulim, Fabien
    Gagnieu, Marie-Claude
    BMC INFECTIOUS DISEASES, 2014, 14
  • [42] Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia
    J. A. Mira
    K. Neukam
    L. F. López-Cortés
    A. Rivero-Juárez
    F. Téllez
    J. A. Girón-González
    I. de los Santos-Gil
    G. Ojeda-Burgos
    D. Merino
    M. J. Ríos-Villegas
    A. Collado
    A. Torres-Cornejo
    J. Macías
    A. Rivero
    M. Pérez-Pérez
    J. A. Pineda
    European Journal of Clinical Microbiology & Infectious Diseases, 2015, 34 : 1879 - 1884
  • [43] Peritransplant treatment with Direct Acting Antivirals of HIV-HCV coinfected patients
    Vinaixa, Carmen
    Aguilera, Victoria
    Rubin, Angel
    Garcia, Maria
    Blanes, Marino
    Benlloch, Salvador
    Prieto, Martin
    Berenguer, Marina
    Juan, Fernando San
    HEPATOLOGY, 2016, 64 : 807A - 808A
  • [44] The risk of infections in HIV-HCV coinfected patients during antiviral therapy with pegIFN+RBV
    Payer, B. A.
    Reiberger, T.
    Breitenecker, F.
    Aichelburg, M. C.
    Schuster, C.
    Heil, P. M.
    Scherzer, T. M.
    Ferenci, P.
    Rieger, A.
    Peck-Radosavljevic, M.
    JOURNAL OF INFECTION, 2012, 65 (02) : 142 - 149
  • [45] Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients
    Giorgiana Hatu
    François Bailly
    Emmanuel Pourcelot
    Pierre Pradat
    Patrick Miailhes
    Marianne Maynard
    François Parant
    Pierre Chiarello
    Jean-Michel Livrozet
    Fabien Zoulim
    Marie-Claude Gagnieu
    BMC Infectious Diseases, 14
  • [46] Virologic and immunologic efficacy of tipranavir/ritonavir monotherapy in a HIV-HCV coinfected patient
    Gomez-Rivas, Paula
    Ramon Blanco, Jose
    Obaldia, Carmen
    Antonio Oteo, Jose
    PHARMACY WORLD & SCIENCE, 2010, 32 (02): : 300 - 300
  • [47] Sustained Virological Response and Baseline Predictors in HIV-HCV Coinfected Patients Retreated with Pegylated Interferon and Ribavirin after Failing a Previous Interferon-Based Therapy: Systematic Review and Meta-Analysis
    Basso, Monica
    Parisi, Saverio Giuseppe
    Mengoli, Carlo
    Gentilini, Valeria
    Menegotto, Nicola
    Monticelli, Jacopo
    Nicole, Stefano
    Cruciani, Mario
    Palu, Giorgio
    HIV CLINICAL TRIALS, 2013, 14 (04): : 127 - 139
  • [48] Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors
    Bani-Sadr, F
    Carrat, F
    Bedossa, P
    Piroth, L
    Cacoub, P
    Perronne, C
    Degott, C
    Pol, S
    AIDS, 2006, 20 (04) : 525 - 531
  • [49] HIV-HCV RNA loads and liver failure in coinfected patients with coagulopathy
    Dragoni, F
    Cafolla, A
    Gentile, G
    Mazzucconi, MG
    Vella, S
    Di Corpo, U
    Tosti, ME
    Pisani, G
    Donato, V
    Martino, P
    HAEMATOLOGICA, 1999, 84 (06) : 525 - 529
  • [50] Efficacy, safety and pharmacokinetics of boceprevir in HIV/HCV-coinfected patients failing PEG-interferon/ribavirin (ANRS HC27 BOCEPREVIH study)
    Fougerou-Leurent, C.
    Poizot-Martin, I.
    Tual, C.
    Laforest, C.
    Danjou, H.
    Renault, A.
    Garraffo, R.
    Colson, P.
    Piroth, L.
    Solas, C.
    Bourliere, M.
    Ghosn, J.
    Alric, L.
    Bertucci, I.
    Diallo, A.
    Molina, J. M.
    Bellissant, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 20 - 20
12345